Dillon Michael P. 4
4 · IDEAYA Biosciences, Inc. · Filed Sep 9, 2021
Insider Transaction Report
Form 4
Dillon Michael P.
SVP, Chief Scientific Officer
Transactions
- Sale
Common Stock
2021-09-07$27.46/sh−116$3,185→ 78,789 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-09-07−116→ 66,119 totalExercise: $4.31Exp: 2028-02-26→ Common Stock (116 underlying) - Exercise/Conversion
Common Stock
2021-09-08$11.08/sh+4,313$47,788→ 90,173 total - Sale
Common Stock
2021-09-08$27.41/sh−11,184$306,559→ 78,989 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-09-08−7,071→ 59,048 totalExercise: $4.31Exp: 2028-02-26→ Common Stock (7,071 underlying) - Exercise/Conversion
Common Stock
2021-09-08$4.31/sh+7,071$30,476→ 85,860 total - Sale
Common Stock
2021-09-08$27.67/sh−200$5,534→ 78,789 total - Exercise/Conversion
Common Stock
2021-09-07$4.31/sh+116$500→ 78,905 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-09-08−4,313→ 24,937 totalExercise: $11.08Exp: 2029-03-13→ Common Stock (4,313 underlying)
Footnotes (5)
- [F1]The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
- [F2]This transaction was executed in multiple trades in prices ranging from $27.45 to $27.50, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F3]This transaction was executed in multiple trades in prices ranging from $26.56 to $27.52, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F4]25% of the shares subject to the option vest on the first anniversary measured from February 27, 2018 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
- [F5]25% of the shares subject to the option vest on the first anniversary measured from February 19, 2019 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.